If you or a loved one has developed persistent nausea, vomiting, or abdominal pain after starting Ozempic, you may be concerned about gastroparesis. Building on decades of medical research into medication side effects, this page reviews published case reports and FDA labeling to clarify the link between semaglutide and delayed gastric emptying.
Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes and for chronic weight management. Among its known adverse effects, gastrointestinal complications are prominent. Clinical trial data show that gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%), with the majority of reports of nausea, vomiting, and/or diarrhea occurring during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions compared to placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In trials with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) versus Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).
Gastroparesis is a condition characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. The clinical presentation of gastroparesis overlaps with the gastrointestinal adverse effects reported with Ozempic, raising concern that the drug may induce or exacerbate this condition. Mechanistically, GLP-1 receptor agonists like semaglutide slow gastric motility as part of their pharmacologic action, which can contribute to delayed gastric emptying. This effect is thought to be mediated through vagal nerve signaling and direct action on gastric smooth muscle. The label for Ozempic acknowledges that there have been rare postmarketing reports of pulmonary aspiration in patients undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). This indicates that delayed gastric emptying can be clinically significant, as retained gastric contents increase aspiration risk. The label further states that available data are insufficient to inform recommendations to mitigate the risk of pulmonary aspiration during general anesthesia or deep sedation in patients taking Ozempic, including whether modifying preoperative fasting recommendations or temporarily discontinuing the drug could reduce the incidence of retained gastric contents (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). Observational evidence suggests that extended GLP-1 RA withholding, 24-hour clear liquid diets, and pre-procedural gastric point-of-care ultrasound may be associated with reduced residual gastric contents in selected patient populations, but the evidence base remains limited, and a modest aspiration risk cannot be excluded (https://pubmed.ncbi.nlm.nih.gov/42245865/). Large, prospective randomized trials are urgently needed to clarify these risks (https://pubmed.ncbi.nlm.nih.gov/42245865/).
The adequacy of warnings regarding Ozempic and gastroparesis is a critical risk anchor. While the label mentions gastrointestinal adverse reactions and rare aspiration events, it does not explicitly warn of gastroparesis as a distinct adverse effect. This gap may leave patients and healthcare providers unaware of the potential for prolonged or severe delayed gastric emptying beyond transient nausea or vomiting. For affected patients, the timeline between exposure and documented harm is variable. Some individuals may develop symptoms during dose escalation, while others may experience delayed onset after months of use. The chronic nature of gastroparesis means that symptoms can persist even after drug discontinuation, leading to long-term morbidity. For patients in Pennsylvania who have developed gastroparesis after using Ozempic, attorney-related considerations are important. The statute of limitations for product liability claims in Pennsylvania is generally two years from the date of injury or from when the injury was discovered or should have been discovered. Given that gastroparesis symptoms may be initially attributed to other causes, the discovery rule may apply, extending the filing deadline. However, patients should consult with a qualified attorney promptly to assess their specific circumstances. Evidence linking Ozempic to gastroparesis includes the drug's known gastrointestinal adverse effects, the mechanistic plausibility of delayed gastric emptying, and postmarketing reports of aspiration due to retained gastric contents. The limited evidence base and lack of explicit warnings may support claims of inadequate labeling. In summary, Ozempic use is associated with a high incidence of gastrointestinal adverse reactions, and the drug's pharmacologic effect on gastric motility raises concern for gastroparesis. The label acknowledges rare aspiration events due to retained gastric contents but does not provide clear guidance on gastroparesis risk. Patients in Pennsylvania who have developed gastroparesis after using Ozempic should be aware of the two-year statute of limitations and seek legal advice to evaluate potential claims.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Request archival records or inquire about member-exclusive transition and benefit programs.
In Pennsylvania, the statute of limitations for product liability claims is generally two years from the date of injury or from when the injury was discovered or should have been discovered. For gastroparesis, symptoms may be initially misattributed, so the discovery rule could extend the deadline. It is crucial to consult with a qualified attorney promptly to evaluate your specific case.
Ozempic (semaglutide) is known to cause gastrointestinal adverse reactions, including nausea, vomiting, and diarrhea, which overlap with gastroparesis symptoms. The drug slows gastric motility, and there have been postmarketing reports of pulmonary aspiration due to retained gastric contents, indicating clinically significant delayed gastric emptying. However, the label does not explicitly warn of gastroparesis as a distinct adverse effect.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.